☰

Jacob E. Koskimaki, Ph.D. - Publications

Affiliations: 
2012 Johns Hopkins University, Baltimore, MD 
Area:
Biomedical Engineering, Oncology, Bioinformatics Biology
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Scientific Reports. 4: 7139. PMID 25409905 DOI: 10.1038/Srep07139  0.821
2014 Rosca EV, Penet MF, Mori N, Koskimaki JE, Lee E, Pandey NB, Bhujwalla ZM, Popel AS. A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. Plos One. 9: e111901. PMID 25384034 DOI: 10.1371/Journal.Pone.0111901  0.816
2013 Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials. 34: 7544-51. PMID 23849876 DOI: 10.1016/J.Biomaterials.2013.06.044  0.668
2013 Lee E, Koskimaki JE, Pandey NB, Popel AS. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia (New York, N.Y.). 15: 112-24. PMID 23441126 DOI: 10.1593/Neo.121638  0.815
2013 Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis. 16: 159-70. PMID 23053781 DOI: 10.1007/S10456-012-9308-7  0.804
2012 Koskimaki JE, Rosca EV, Rivera CG, Lee E, Chen W, Pandey NB, Popel AS. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Translational Oncology. 5: 92-7. PMID 22496925 DOI: 10.1593/Tlo.11244  0.81
2012 Rosca EV, Lal B, Koskimaki JE, Popel AS, Laterra J. Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth. Anti-Cancer Drugs. 23: 706-12. PMID 22495619 DOI: 10.1097/Cad.0B013E3283531041  0.746
2012 Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS. Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides. Chemical Biology & Drug Design. 80: 27-37. PMID 22405100 DOI: 10.1111/J.1747-0285.2012.01376.X  0.739
2011 Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS. Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biology & Therapy. 12: 808-17. PMID 21878750 DOI: 10.4161/Cbt.12.9.17677  0.82
2011 Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. Journal of Medicinal Chemistry. 54: 6492-500. PMID 21866962 DOI: 10.1021/Jm200114F  0.772
2011 Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS. Anti-angiogenic peptides for cancer therapeutics. Current Pharmaceutical Biotechnology. 12: 1101-16. PMID 21470139 DOI: 10.2174/138920111796117300  0.756
2011 Rosca EV, Penet M, Koskimaki JE, Pandey NB, Bhujwalla ZM, Popel AS. Abstract 4267: Biomimetic anti-angiogenic peptide as therapeutic agent for breast cancer Cancer Research. 71: 4267-4267. DOI: 10.1158/1538-7445.Am2011-4267  0.793
2010 Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. Bmc Cancer. 10: 29. PMID 20122172 DOI: 10.1186/1471-2407-10-29  0.79
2010 Rosca EV, Koskimaki JE, Popel AS. Abstract 1365: Novel anti-angiogenic peptides as potential therapeutic agents in combination with chemotherapy for breast cancer Cancer Research. 70: 1365-1365. DOI: 10.1158/1538-7445.Am10-1365  0.798
2009 Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT, Raman V, Bhujwalla ZM, Popel AS. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (New York, N.Y.). 11: 1285-91. PMID 20019836 DOI: 10.1593/Neo.09620  0.814
Show low-probability matches.